The acquisition of Switzerland's PolyPeptide Group by Samsung Biologics (KRX:207940) is scheduled for settlement on Nov. 30, under a cash tender offer valued at 2.706 trillion won.
The board-approved plan targets 33 million shares, representing a 100% stake, according to parent Samsung C&T's (KRX:028260) bourse filing on Tuesday.
The target's largest shareholder, Draupnir Holding, has already committed to tendering its 55.65% stake, though the offer hinges on a minimum tender condition of roughly two-thirds of the fully diluted share capital.